ProPhase Labs, Inc. ('ProPhase” or the 'Company”), a diversified life sciences and diagnostics company, today announced that its common stock has been approved and uplisted from the Pink Sheets to the ...

ProPhase Labs' recent 52-week low is reflective of broader challenges faced by the company, as highlighted by several InvestingPro metrics and tips. The company's market capitalization stands at a ...

Garden City, NY, April 28, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, is pleased to announce that Ted Karkus ...

ProPhase Labs announced plans to launch DNA Complete and DNA Expand, scale up operations at PMI, and implement cost reduction plans. The company aims to reduce overhead costs by $6 million, which ...

ProPhase Labs, Inc. (PRPH) shares ended the last trading session 8.5% higher at $8.42. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

最近の 分析 利益 記録 会社 アナリスト評価 インサイダー取引 SEC年次報告書 Pro プロフェース・ラブス（Prophase Labs Inc）は、メディカルサイエンスとテクノロジーを提供する企業である。【事業内容】消費者向け製品と診断サービスの2つのセグメントで事業 ...

Company Actively Pursuing Strategic Alternatives Including the Potential Sale of Nebula Genomics and DNA Complete to Unlock Immediate Cash GARDEN CITY, NY, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ProPhase ...

ProPhase Labs is a diversified biotech company with profitable existing product lines and plans for expansion. The company's subsidiary, Nebula Genomics, offers whole genome sequencing and plans to ...